Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TK002
- Development stage
- Preclinical
- Lead developer
- Takis
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
TK002 is a bispecific T cell engager (BiTE) developed by Takis for the treatment of solid tumors. It is designed to simultaneously target the ErbB3 (HER3) receptor, which is often overexpressed in various cancers and associated with therapy resistance, and the CD3 molecule on T cells. By bridging these two targets, TK002 redirects T-cell-mediated cytotoxicity specifically toward ErbB3-positive tumor cells. Currently in preclinical development, it has been investigated for potential use in treating various solid tumors, including colonic, prostatic, and stomach cancers.
- Other names
- ErbB3xCD3 bispecific T cell engagerErbB-3xCD3 bispecific T cell engagerErbB 3xCD3 bispecific T cell engagerHER3xCD3 bispecific antibodyHER-3xCD3 bispecific antibodyHER 3xCD3 bispecific antibody
02
Targets
CD3 (T-cell surface glycoprotein CD3)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on TK002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TK002.